A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

NCT01478685 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

169

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms
Carcinoma, Transitional Cell
Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Pancreatic Ductal
Tumor Virus Infections

Interventions

DRUG: CC-486
DRUG: Carboplatin
DRUG: ABI-007

Sponsor

Celgene